LY2409021 + ketoconazole

LY2409021 + ketoconazole is a combination of two drugs: **LY2409021**, a small molecule glucagon receptor antagonist being evaluated for the treatment of type 2 diabetes, and **ketoconazole**, a potent antifungal agent and a strong CYP3A4 inhibitor. LY2409021 works by competitively inhibiting the glucagon receptor, reducing hepatic glucose output, and thereby lowering blood glucose. Ketoconazole is included here principally as a CYP3A4 inhibitor, often used in drug-drug interaction studies to assess changes in LY2409021 pharmacokinetics in the presence of strong CYP3A4 inhibition. LY2409021 was developed by Eli Lilly primarily for type 2 diabetes and studied in various phases. Ketoconazole is manufactured by several companies worldwide and widely used clinically for fungal infections, but in this context serves to alter metabolism of LY2409021 for research purposes[4][2][1].